by | May 13, 2024 | Publications
Blood Adv. 2024 May 13:bloodadvances.2023012539. doi: 10.1182/bloodadvances.2023012539. Online ahead of print. ABSTRACT In newly diagnosed transplant-ineligible patients with myeloma, daratumumab has improved outcomes when added to the standard of care regimens. In a...
by | May 13, 2024 | Publications
MedComm (2020). 2024 May 9;5(5):e562. doi: 10.1002/mco2.562. eCollection 2024 May. ABSTRACT The proteasome inhibitor bortezomib (BTZ) is the first-line therapy for multiple myeloma (MM). BTZ resistance largely limits its clinical application in MM. Interleukin-33...
by | May 13, 2024 | Publications
Cureus. 2024 Apr 11;16(4):e58066. doi: 10.7759/cureus.58066. eCollection 2024 Apr. ABSTRACT Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow, often leading to various end-organ damages. Here, we...
by | May 13, 2024 | Publications
Expert Opin Biol Ther. 2024 May 13. doi: 10.1080/14712598.2024.2352591. Online ahead of print. ABSTRACT INTRODUCTION: Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting CAR-T therapy, is approved in the United States and Europe for patients with...
by | May 13, 2024 | Publications
Acta Haematol. 2024 May 10. doi: 10.1159/000539127. Online ahead of print. ABSTRACT INTRODUCTION: Most multiple myeloma (MM) patients experience cytopenias, likely driven by both disease and treatment-related factors. Immunomodulatory agents (IMiDs), which form the...
by | May 12, 2024 | Publications
Int Immunopharmacol. 2024 May 10;134:112043. doi: 10.1016/j.intimp.2024.112043. Online ahead of print. ABSTRACT Multiple myeloma (MM), a malignancy of plasma cells, is an incurable disease that is characterized by the neoplastic proliferation of plasma cells leading...
